Teacher Retirement System of Texas Reduces Stock Position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

Teacher Retirement System of Texas decreased its holdings in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 3.8% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 637,877 shares of the company's stock after selling 24,920 shares during the quarter. Teacher Retirement System of Texas owned approximately 0.06% of Teva Pharmaceutical Industries worth $9,804,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. WCM Investment Management LLC grew its holdings in Teva Pharmaceutical Industries by 57.0% during the first quarter. WCM Investment Management LLC now owns 213,157 shares of the company's stock worth $3,214,000 after purchasing an additional 77,403 shares during the period. DAVENPORT & Co LLC increased its holdings in shares of Teva Pharmaceutical Industries by 23.4% during the first quarter. DAVENPORT & Co LLC now owns 470,828 shares of the company's stock worth $7,237,000 after purchasing an additional 89,340 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd increased its stake in Teva Pharmaceutical Industries by 11.3% in the first quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 117,256 shares of the company's stock valued at $1,802,000 after acquiring an additional 11,912 shares during the last quarter. KBC Group NV increased its stake in Teva Pharmaceutical Industries by 26.2% in the first quarter. KBC Group NV now owns 46,916 shares of the company's stock valued at $721,000 after acquiring an additional 9,753 shares during the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. increased its stake in Teva Pharmaceutical Industries by 5.7% in the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,504,007 shares of the company's stock valued at $38,487,000 after acquiring an additional 134,705 shares during the last quarter. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Price Performance

TEVA stock remained flat at $17.05 during trading on Friday. 5,550,481 shares of the company's stock were exchanged, compared to its average volume of 10,281,000. Teva Pharmaceutical Industries Ltd. has a twelve month low of $12.47 and a twelve month high of $22.80. The company has a debt-to-equity ratio of 2.59, a current ratio of 1.03 and a quick ratio of 0.74. The stock has a 50 day moving average price of $16.99 and a 200 day moving average price of $17.34. The stock has a market cap of $19.56 billion, a P/E ratio of -14.83, a price-to-earnings-growth ratio of 0.87 and a beta of 0.60.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The company reported $0.52 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.47 by $0.05. The business had revenue of $3.89 billion during the quarter, compared to the consensus estimate of $3.99 billion. Teva Pharmaceutical Industries had a negative net margin of 7.74% and a positive return on equity of 45.44%. The firm's quarterly revenue was up 1.9% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.48 EPS. As a group, research analysts predict that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current fiscal year.

Analysts Set New Price Targets

TEVA has been the topic of a number of research analyst reports. UBS Group cut their target price on shares of Teva Pharmaceutical Industries from $24.00 to $23.00 and set a "buy" rating on the stock in a research report on Thursday, June 26th. The Goldman Sachs Group started coverage on shares of Teva Pharmaceutical Industries in a report on Friday, June 6th. They issued a "buy" rating and a $24.00 target price on the stock. Hsbc Global Res raised shares of Teva Pharmaceutical Industries to a "strong-buy" rating in a research note on Monday, April 28th. Wall Street Zen raised shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research note on Thursday, May 22nd. Finally, JPMorgan Chase & Co. raised shares of Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and boosted their target price for the stock from $21.00 to $23.00 in a research report on Monday, May 12th. Eight investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus price target of $24.13.

Insiders Place Their Bets

In other Teva Pharmaceutical Industries news, EVP Matthew Shields sold 6,206 shares of the business's stock in a transaction dated Tuesday, June 3rd. The shares were sold at an average price of $17.02, for a total value of $105,626.12. Following the transaction, the executive vice president directly owned 9,989 shares in the company, valued at $170,012.78. The trade was a 38.32% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.49% of the stock is currently owned by insiders.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.